These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1823391)

  • 1. Total body bone mineral and tartrate-resistant acid phosphatase levels in type I and III osteogenesis imperfecta.
    Rico H; Revilla M; Iritia M; Arribas I; Fernando Villa L
    Miner Electrolyte Metab; 1991; 17(6):396-8. PubMed ID: 1823391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biological profile and value of determination of tartrate-resistant acid phosphatase in children].
    Rico Lenza H; Revilla Amores M; Iritia Bartolomé M; Arribas Gómez I
    An Esp Pediatr; 1991 Apr; 34(4):289-91. PubMed ID: 2069278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biological profile of tartrate-resistant acid phosphatase as a marker of bone resorption].
    Rico H; Iritia M; Arribas I; Revilla M
    Rev Esp Fisiol; 1990 Dec; 46(4):379-83. PubMed ID: 2099535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that abnormal high bone mineralization in growing children with osteogenesis imperfecta is not associated with specific collagen mutations.
    Roschger P; Fratzl-Zelman N; Misof BM; Glorieux FH; Klaushofer K; Rauch F
    Calcif Tissue Int; 2008 Apr; 82(4):263-70. PubMed ID: 18311573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme histochemical localisation of alkaline phosphatase activity in osteogenesis imperfecta bone and growth plate: a preliminary study.
    Sarathchandra P; Cassella JP; Ali SY
    Micron; 2005; 36(7-8):715-20. PubMed ID: 16182549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect.
    Glorieux FH; Ward LM; Rauch F; Lalic L; Roughley PJ; Travers R
    J Bone Miner Res; 2002 Jan; 17(1):30-8. PubMed ID: 11771667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteogenesis imperfecta: changes in noncollagenous proteins in bone.
    Vetter U; Fisher LW; Mintz KP; Kopp JB; Tuross N; Termine JD; Robey PG
    J Bone Miner Res; 1991 May; 6(5):501-5. PubMed ID: 2068957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations.
    Garnero P; Schott AM; Prockop D; Chevrel G
    Bone; 2009 Mar; 44(3):461-6. PubMed ID: 19071236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bone mineral content in osteogenesis imperfecta].
    Rajtár M; László A; Beviz J; Bossányi A; Almási L; Csernay L
    Orv Hetil; 1996 Jul; 137(28):1519-23. PubMed ID: 8757074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro expression of osteoblastic markers in cells isolated from normal fetal and postnatal human bone and from bone of patients with osteogenesis imperfecta.
    Mörike M; Schulz M; Brenner RE; Bushart GB; Teller WM; Vetter U
    J Cell Physiol; 1993 Dec; 157(3):439-44. PubMed ID: 8253854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone turnover markers in patients with osteogenesis imperfecta.
    Braga V; Gatti D; Rossini M; Colapietro F; Battaglia E; Viapiana O; Adami S
    Bone; 2004 Jun; 34(6):1013-6. PubMed ID: 15193547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Role of the bone mineral density investigation through measuring of peripheral dual-energetic x-ray absorption in prevention of fractures in children with osteogenesis imperfecta].
    Saganelidze KhZ
    Georgian Med News; 2005 Mar; (120):61-4. PubMed ID: 15855703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
    Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
    Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
    Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
    Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alendronate treatment in osteogenesis imperfecta.
    Madenci E; Yilmaz K; Yilmaz M; Coskun Y
    J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do patients with osteogenesis imperfecta need individualized nutritional support?
    Chagas CE; Roque JP; Santarosa Emo Peters B; Lazaretti-Castro M; Martini LA
    Nutrition; 2012 Feb; 28(2):138-42. PubMed ID: 21795023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous pamidronate in osteogenesis imperfecta type VII.
    Cheung MS; Glorieux FH; Rauch F
    Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of densitometric measurement in selected pediatric subject.
    Lorenc RS; Matusik H; Olszaniecka M; Lebiedowski M
    Acta Univ Carol Med (Praha); 1994; 40(1-4):23-8. PubMed ID: 9355667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.